Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-628 in Adult Focal or Generalized Tonic-Clonic Seizures
NCT06908356Phase 2Recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Classical Binding Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of vormatrigine in focal onset seizure, generalized tonic-clonic seizure (GTCS), sponsored by Praxis Precision Medicines. Started Jan 2025; status: recruiting.
02
Drugs
vormatrigine
03
Conditions
focal onset seizuregeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on NCT06908356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908356.